Recent Advances in Neuroblastoma

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2010 Jun 19

PMID 20558371

Citations 1014

Authors

John M Maris

Affiliations

Soon will be listed here.

Citing Articles

Risk stratification in neuroblastoma patients through machine learning in the multicenter PRIMAGE cohort.

Lozano-Montoya J, Jimenez-Pastor A, Fuster-Matanzo A, Weiss G, Cerda-Alberich L, Veiga-Canuto D Front Oncol. 2025; 15:1528836.

PMID: 40061893 PMC: 11886962. DOI: 10.3389/fonc.2025.1528836.

Investigation of the Effects of Polyunsaturated Fatty Acid Ratios in Human SH-SY5Y Cells by Methods.

Elci M, Fatsa T, Oren S, Miser Salihoglu E, Akaydin S Turk J Pharm Sci. 2025; 22(1):10-18.

PMID: 40052338 PMC: 11887594. DOI: 10.4274/tjps.galenos.2024.40583.

Antitumor Activity, Mechanisms of Action and Phytochemical Profiling of Sub-Fractions Obtained from Planch. (Fabaceae): A Medicinal Plant from Galicia (Spain).

Bada L, Butt H, Quezada E, Picos A, Wangensteen H, Inngjerdingen K Molecules. 2025; 30(4).

PMID: 40005281 PMC: 11858089. DOI: 10.3390/molecules30040972.

Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma.

Chugh S, Tien J, Hon J, Kenum C, Mannan R, Cheng Y Neoplasia. 2025; 60:100964.

PMID: 39900433 PMC: 11846495. DOI: 10.1016/j.neo.2024.100964.

Global, regional and national burden of neuroblastoma and other peripheral nervous system tumors, 1990 to 2021 and predictions to 2035: visualizing epidemiological characteristics based on GBD 2021.

Yue C, Zhang Q, Sun F, Pan Q Neoplasia. 2025; 60:101122.

PMID: 39855015 PMC: 11795104. DOI: 10.1016/j.neo.2025.101122.

References

COLE W, EVERSON T . Spontaneous regression of cancer: preliminary report. Ann Surg. 1956; 144(3):366-83. PMC: 1465423. DOI: 10.1097/00000658-195609000-00007. View

Langler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F . Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study. Klin Padiatr. 2002; 214(4):153-6. DOI: 10.1055/s-2002-33175. View

Yamamoto K, Hanada R, Kikuchi A, Ichikawa M, Aihara T, Oguma E . Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol. 1998; 16(4):1265-9. DOI: 10.1200/JCO.1998.16.4.1265. View

DAngio G, Evans A, KOOP C . Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet. 1971; 1(7708):1046-9. DOI: 10.1016/s0140-6736(71)91606-0. View

Matthay K . Stage 4S neuroblastoma: what makes it special?. J Clin Oncol. 1998; 16(6):2003-6. DOI: 10.1200/JCO.1998.16.6.2003. View

Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, De Pontual L, Combaret V . Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008; 455(7215):967-70. DOI: 10.1038/nature07398. View

Shusterman S, London W, Gillies S, Hank J, Voss S, Seeger R . Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010; 28(33):4969-75. PMC: 3020698. DOI: 10.1200/JCO.2009.27.8861. View

Matthay K, Tan J, Villablanca J, Yanik G, Veatch J, Franc B . Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006; 24(3):500-6. DOI: 10.1200/JCO.2005.03.6400. View

Cheung N, Lazarus H, MIRALDI F, Abramowsky C, Kallick S, Saarinen U . Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987; 5(9):1430-40. DOI: 10.1200/JCO.1987.5.9.1430. View

10.

Beiske K, Burchill S, Cheung I, Hiyama E, Seeger R, Cohn S . Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer. 2009; 100(10):1627-37. PMC: 2696761. DOI: 10.1038/sj.bjc.6605029. View

11.

Trochet D, Bourdeaut F, Janoueix-Lerosey I, Deville A, De Pontual L, Schleiermacher G . Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet. 2004; 74(4):761-4. PMC: 1181953. DOI: 10.1086/383253. View

12.

George R, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger R . High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006; 24(18):2891-6. DOI: 10.1200/JCO.2006.05.6986. View

13.

Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola M, Viscardi E . A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003; 98(11):2488-94. DOI: 10.1002/cncr.11797. View

14.

Sidell N . Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst. 1982; 68(4):589-96. View

15.

Carlsen N . How frequent is spontaneous remission of neuroblastomas? Implications for screening. Br J Cancer. 1990; 61(3):441-6. PMC: 1971306. DOI: 10.1038/bjc.1990.97. View

16.

Kushner B, LaQuaglia M, Bonilla M, Lindsley K, Rosenfield N, Yeh S . Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol. 1994; 12(12):2607-13. DOI: 10.1200/JCO.1994.12.12.2607. View

17.

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

18.

Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H . Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006; 98(17):1193-203. DOI: 10.1093/jnci/djj330. View

19.

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

20.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View